DENIS M. MCCARTHY, M.D., M. SC.
This content is PDF only. Please click on the PDF icon to access.
Physicians in the United States are now getting their first experience with ranitidine HCL (Zantac; Glaxo Inc., Fort Lauderdale, Florida), a new H2-receptor blocking antihistamine that inhibits gastric acid secretion with a potency four- to eightfold that of cimetidine (1, 2). In June, the FDA approved marketing of the drug for short-term oral use in the treatment of duodenal ulcer and for unrestricted use in hypersecretory states, such as the Zollinger-Ellison syndrome. The drug is not yet approved for gastric ulcer, maintenance therapy in duodenal ulcers, or parenteral use. Ranitidine received a therapeutic rating of 1C, which the FDA assigns
MCCARTHY DM. Ranitidine or Cimetidine. Ann Intern Med. 1983;99:551–553. doi: https://doi.org/10.7326/0003-4819-99-4-551
Download citation file:
Published: Ann Intern Med. 1983;99(4):551-553.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use